Abstract
The first generation of in silico hERG models have focused on key driving forces for hERG/ligand binding: basicity and lipophilicity. While reducing basicity and lipophilicity are typically the first line approaches to eliminating hERG blocking activity, in many programs these are not feasible approaches because basicity and lipophilicity are frequently necessary for achieving good pharmacokinetics or primary target binding. Thus for the second, generation of in silico hERG models, a focus on understanding the more subtle aspects of hERG binding is necessary. Thus, the focus of this review is on extracting ideas, either qualitative or quantitative, from the various modeling efforts as to how hERG activity might be eliminated or diminished beyond simply reducing basicity and lipophilicity. In addition, several areas where key questions around hERG binding have not been adequately addressed by in silico work are highlighted.
Current Computer-Aided Drug Design
Title: In Silico hERG Modeling: Challenges and Progress
Volume: 5 Issue: 2
Author(s): David J. Diller
Affiliation:
Abstract: The first generation of in silico hERG models have focused on key driving forces for hERG/ligand binding: basicity and lipophilicity. While reducing basicity and lipophilicity are typically the first line approaches to eliminating hERG blocking activity, in many programs these are not feasible approaches because basicity and lipophilicity are frequently necessary for achieving good pharmacokinetics or primary target binding. Thus for the second, generation of in silico hERG models, a focus on understanding the more subtle aspects of hERG binding is necessary. Thus, the focus of this review is on extracting ideas, either qualitative or quantitative, from the various modeling efforts as to how hERG activity might be eliminated or diminished beyond simply reducing basicity and lipophilicity. In addition, several areas where key questions around hERG binding have not been adequately addressed by in silico work are highlighted.
Export Options
About this article
Cite this article as:
Diller J. David, In Silico hERG Modeling: Challenges and Progress, Current Computer-Aided Drug Design 2009; 5 (2) . https://dx.doi.org/10.2174/157340909788451928
DOI https://dx.doi.org/10.2174/157340909788451928 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Risk Factors and Potential Preventive Measures for Vascular Disease Progression in Hemodialysis Patients
Vascular Disease Prevention (Discontinued) Relationship Between Inflammation, Insulin Resistance and Type 2 Diabetes: Cause or Effect?
Current Diabetes Reviews Evaluation of Echocardiographic Abnormalities in HIV Positive Patients Treated with Antiretroviral Medications
Infectious Disorders - Drug Targets Cardiac Regeneration by Progenitor Cells: What Is It Known as and What Is It Still to Be Known as?
Cardiovascular & Hematological Agents in Medicinal Chemistry The Meaning of Different Forms of Structural Myocardial Injury, Immune Response and Timing of Infarct Necrosis and Cardiac Repair
Current Vascular Pharmacology Treatments for Obesity-Related Hypertension
Current Hypertension Reviews Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design The Endocannabinoid System: A Promising Target for the Management of Type 2 Diabetes
Current Protein & Peptide Science Essential Oils with Microbicidal and Antibiofilm Activity
Current Pharmaceutical Biotechnology Abdominal Aortic Aneurysm: What About Screening?
Current Pharmaceutical Design Aldosterone Receptor Antagonists and Cardiovascular Disease: Do We Need a Change of the Guard?
Cardiovascular & Hematological Agents in Medicinal Chemistry Primary Prevention of Cardiovascular Risk in Octogenarians by Risk Factors Control
Current Hypertension Reviews Statins in Aortic Stenosis
Current Pharmaceutical Design Hesperidin Potentiates Ghrelin Signaling
Recent Patents on Food, Nutrition & Agriculture Current Evidence for Antithrombotic Therapy after Peripheral Vascular Interventions
Current Vascular Pharmacology Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
Current Pharmaceutical Design Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Outline of Proteins and Signaling Pathways Involved in Heart Failure
Current Protein & Peptide Science Role of Nitric Oxide and Mitochondrial Nitric Oxide Synthase in Energy Adaptive Responses
Current Cardiology Reviews